Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

  • Author(s): Ustun, Celalettin
  • Morgan, Elizabeth
  • Moodie, Erica EM
  • Pullarkat, Sheeja
  • Yeung, Cecilia
  • Broesby-Olsen, Sigurd
  • Ohgami, Robert
  • Kim, Young
  • Sperr, Wolfgang
  • Vestergaard, Hanne
  • Chen, Dong
  • Kluin, Philip M
  • Dolan, Michelle
  • Mrózek, Krzysztof
  • Czuchlewski, David
  • Horny, Hans-Peter
  • George, Tracy I
  • Kristensen, Thomas Kielsgaard
  • Ku, Nam K
  • Yi, Cecilia Arana
  • Møller, Michael Boe
  • Marcucci, Guido
  • Baughn, Linda
  • Schiefer, Ana-Iris
  • Hilberink, JR
  • Pullarkat, Vinod
  • Shanley, Ryan
  • Kohlschmidt, Jessica
  • Coulombe, Janie
  • Salhotra, Amandeep
  • Soma, Lori
  • Cho, Christina
  • Linden, Michael A
  • Akin, Cem
  • Gotlib, Jason
  • Hoermann, Gregor
  • Hornick, Jason
  • Nakamura, Ryo
  • Deeg, Joachim
  • Bloomfield, Clara D
  • Weisdorf, Daniel
  • Litzow, Mark R
  • Valent, Peter
  • Huls, Gerwin
  • Perales, Miguel-Angel
  • Borthakur, Gautam
  • et al.

Published Web Location

https://doi.org/10.1002/cam4.1733
Abstract

Background

Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.

Methods

Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).

Results

Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001).

Conclusions

I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View